Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan Purchases 56,054 Shares of Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Robert W. Duggan bought 56,054 shares of Pulse Biosciences stock in a transaction on Wednesday, December 11th. The stock was acquired at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the transaction, the director now directly owns 42,228,057 shares of the company’s stock, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulse Biosciences Trading Up 3.0 %

Shares of PLSE opened at $17.65 on Friday. The firm has a 50-day simple moving average of $17.68 and a two-hundred day simple moving average of $16.40. Pulse Biosciences, Inc. has a 1-year low of $6.59 and a 1-year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period in the previous year, the firm earned ($0.19) EPS.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently modified their holdings of PLSE. Vanguard Group Inc. grew its stake in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares in the last quarter. State Street Corp raised its holdings in Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after acquiring an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Pulse Biosciences in the third quarter worth approximately $588,000. Finally, Geode Capital Management LLC grew its holdings in Pulse Biosciences by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after acquiring an additional 33,200 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Thursday.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.